Verve Therapeutics Statistics
Total Valuation
Zoono Group has a market cap or net worth of 7.34 million. The enterprise value is 7.30 million.
| Market Cap | 7.34M |
| Enterprise Value | 7.30M |
Important Dates
The next estimated earnings date is Wednesday, August 20, 2025.
| Earnings Date | Aug 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 355.43M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +66.14% |
| Shares Change (QoQ) | +43.33% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 186.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.74 |
| PB Ratio | 2.26 |
| P/TBV Ratio | 2.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.89 |
| EV / Sales | 11.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.35, with a Debt / Equity ratio of 0.12.
| Current Ratio | 8.35 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -62.17 |
Financial Efficiency
Return on equity (ROE) is -79.40% and return on invested capital (ROIC) is -37.60%.
| Return on Equity (ROE) | -79.40% |
| Return on Assets (ROA) | -28.00% |
| Return on Invested Capital (ROIC) | -37.60% |
| Return on Capital Employed (ROCE) | -51.73% |
| Revenue Per Employee | 625,380 |
| Profits Per Employee | -2.52M |
| Employee Count | 1 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 0.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.25% in the last 52 weeks. The beta is 1.11, so Zoono Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -6.25% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.67 |
| Relative Strength Index (RSI) | 48.36 |
| Average Volume (20 Days) | 2,000 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zoono Group had revenue of 625,380 and -2.52 million in losses. Loss per share was -0.01.
| Revenue | 625,380 |
| Gross Profit | -496,243 |
| Operating Income | -2.27M |
| Pretax Income | -2.52M |
| Net Income | -2.52M |
| EBITDA | -2.23M |
| EBIT | -2.27M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 441,747 in cash and 401,001 in debt, giving a net cash position of 40,746.
| Cash & Cash Equivalents | 441,747 |
| Total Debt | 401,001 |
| Net Cash | 40,746 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 3.25M |
| Book Value Per Share | 0.01 |
| Working Capital | 3.76M |
Cash Flow
| Operating Cash Flow | -1.53M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -79.35% |
| Operating Margin | -363.01% |
| Pretax Margin | -403.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zoono Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -66.14% |
| Shareholder Yield | n/a |
| Earnings Yield | -34.38% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zoono Group has an Altman Z-Score of -0.49 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.49 |
| Piotroski F-Score | 3 |